Coloma Jason V 4

What Happened
Jason V. Coloma, CEO of Maze Therapeutics, sold a total of 1,938 shares on May 15, 2026 in two transactions at $26.00 per share. The two sales were 1,822 shares ($47,372) and 116 shares ($3,016), for combined proceeds of $50,388. These were dispositions (sales), which are typically routine cashing-out events rather than purchases that might signal insider bullishness.

Key Details

• Transaction date and price: May 15, 2026 — 1,822 shares @ $26.00 and 116 shares @ $26.00.
• Total proceeds: $50,388.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes: F1 — sales were effected under a Rule 10b5-1 trading plan adopted Feb 6, 2026; F2/F3 — some securities are held by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust (Coloma and spouse are co-trustees).
• Correction: This Form 4 corrects the reporting of certain holdings previously shown as directly held by Coloma on his Form 3 and restates attribution to the Family Trust and Irrevocable Trust; prior Section 16 reports should be read with this correction.
• Filing timeliness: Form 4 was filed May 18, 2026 (three calendar days after the trades); this appears to be within the normal two-business-day reporting window and is not flagged as late.

Context
Sales under a Rule 10b5-1 plan are prearranged and often reflect scheduled dispositions rather than a real-time view of the company, so they are generally considered routine. The correction about trust ownership affects how Coloma’s holdings are attributed (held by trusts for which he is co‑trustee), which is an administrative clarification rather than a new acquisition or disposition.